Axcan Eyes Photofrin Gastroenterology Promotion; QLT To Focus on Visudyne
QLT Phototherapeutics' sale of Photofrin to fellow Canadian firm Axcan will position the product for a potential Barrett's esophagus indication.
You may also be interested in...
Ciba Vision/QLT PhotoTherapeutics' Visudyne will have an average cost of $4,175.20 per patient, based on a price to doctors of $1,228 per vial, and an average of 3.4 treatments per patient per year.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials